{
    "Clinical Trial ID": "NCT00775645",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I (Acetyl-L-carnitine Hydrochloride))",
        "  Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks",
        "INTERVENTION 2: ",
        "  Arm II (Placebo)",
        "  Patients receive oral placebo 3 times daily for 24 weeks"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed primary invasive adenocarcinoma of the breast",
        "  Stage I-III disease",
        "  No metastatic disease",
        "  Must have undergone modified radical mastectomy or breast-sparing surgery",
        "  Planning to receive one of the following standard taxane-based systemic chemotherapy regimens as adjuvant therapy for breast cancer:",
        "  Paclitaxel 80 mg/m\u00b2 weekly for 12 weeks",
        "  Paclitaxel 175 mg/m\u00b2 every other week for 4 courses (8 weeks)",
        "  Paclitaxel 175 mg/m\u00b2 every other week for 6 courses (12 weeks)",
        "  Docetaxel 75 mg/m\u00b2 every 3 weeks for 4 courses (12 weeks)",
        "  Docetaxel 75 mg/m\u00b2 every 3 weeks for 6 courses (18 weeks)",
        "  No history of neuropathy",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Menopausal status not specified",
        "  Zubrod performance status 0-2",
        "  Serum creatinine  2.5 times upper limit of normal",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception",
        "  Able to complete questionnaires in English or Spanish",
        "  Willing to submit blood samples for DNA extraction, genotyping analysis, and nerve growth factor studies",
        "  No history of diabetes",
        "  No history of seizure disorder",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, ductal carcinoma in situ, or adequately treated stage I or stage II malignancy from which the patient is currently in complete remission",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  Recovered from prior breast surgery",
        "  Prior neoadjuvant or adjuvant chemotherapy allowed",
        "  No prior taxane therapy",
        "  No prior biologic therapy for treatment of breast cancer",
        "  No concurrent vitamin E, glutamine, gabapentin, nortriptyline, amitriptyline, or duloxetine hydrochloride",
        "  Multivitamins containing vitamin E allowed provided vitamin E dose is < 1,000 IU",
        "  No concurrent anti-seizure medications",
        "  Concurrent hormonal therapy allowed",
        "  Concurrent biologic therapy allowed (e.g., Herceptin)",
        "  Concurrent participation in another therapeutic clinical trial allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups",
        "  Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires",
        "  Time frame: 12 weeks post-registration",
        "Results 1: ",
        "  Arm/Group Title: Arm I (Acetyl-L-carnitine Hydrochloride))",
        "  Arm/Group Description: Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks",
        "  Overall Number of Participants Analyzed: 191",
        "  Mean (Full Range)",
        "  Unit of Measure: units on a scale  35.4        (34.1 to 36.7)",
        "Results 2: ",
        "  Arm/Group Title: Arm II (Placebo)",
        "  Arm/Group Description: Patients receive oral placebo 3 times daily for 24 weeks",
        "  Overall Number of Participants Analyzed: 181",
        "  Mean (Full Range)",
        "  Unit of Measure: units on a scale  36.3        (35 to 37.6)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/208 (0.48%)",
        "  Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%)",
        "Adverse Events 2:",
        "  Total: 0/201 (0.00%)",
        "  Neutrophils/granulocytes (ANC/AGC) 0/201 (0.00%)"
    ]
}